Studying DNA in Blood and Bone Marrow Samples From Young Patients With Acute Myeloid Leukemia
Recruitment status was Active, not recruiting
RATIONALE: Studying samples of blood and bone marrow from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how well patients will respond to treatment.
PURPOSE: This research study is looking at the DNA in blood or bone marrow samples from young patients with acute myeloid leukemia (AML).
Genetic: comparative genomic hybridization
Genetic: gene mapping
Genetic: polymorphism analysis
Other: laboratory biomarker analysis
|Official Title:||Genetic Predictors of AML Treatment Response|
- First acute myeloid leukemia relapse [ Designated as safety issue: No ]
- Rate of invasive bacterial infections during the time period at risk (interval between date on study and the last chemotherapy reporting period end date) [ Designated as safety issue: No ]
|Study Start Date:||December 2009|
|Estimated Primary Completion Date:||January 2010 (Final data collection date for primary outcome measure)|
- Perform a genome-wide scan to test for loci associated with acute myeloid leukemia (AML) relapse and infection risk.
- Validate positive associations seen in the genome-wide scan with a fine mapping approach.
- Perform simulated clinical trials using germline genetic variation data to test the feasibility of using genetic data to inform the clinical care of pediatric patients with AML.
OUTLINE: This is a multicenter study.
Germline DNA is obtained from previously collected peripheral blood or bone marrow samples for array-based genotyping studies, including genome-wide association studies (single nucleotide polymorphisms) and fine mapping genotyping.
Clinical trial simulations are performed to test the clinical applicability of using genetic variation data in the management of infectious complications.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01024127
|Study Chair:||Richard Aplenc, MD, MSCE||Children's Hospital of Philadelphia|